Chapter 40: Other Antimicrobial Agents Such as Quinolones and Antifolate Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Hello and welcome back to the Deep Dive.

It is really great to have you with us.

Today, we are opening up what I think is one of the most, well, deceptive chapters in the entire pharmacology textbook.

We are looking at chapter 40 of Brenner and Stevens' Pharmacology, the sixth edition.

It's deceptive because of the title, right?

Exactly.

The title is just Other Antimicrobial Agents.

Hmm, chisterpiece.

It sounds like, you know, the junk drawer in your kitchen.

You have your silverware drawer, that's your penicillins.

You have your utensil drawer, maybe the tetracyclines, and then you have that other drawer.

Yeah, where you just throw the rubber bands and the spare batteries and like a tube of super glue.

Exactly.

And that is such a common misconception.

I think students see other and their brain immediately translates that to optional.

But, you know, in reality, this is not the junk drawer.

This is the special ops armory.

It's special ops armory.

I like that a lot.

Yeah, we aren't talking about leftovers here.

We are talking about drugs that are designed for very specific, very high stakes missions.

We're talking about drugs you use when you need to, say, shut down a factory line of bacterial reproduction.

Okay.

Or when you need to physically snap a bacterium's DNA in half.

Oh.

Or even dissolve its cell membrane, like you're using some kind of industrial detergent.

That sounds significantly more intense than a junk drawer.

It is.

I mean, these are the drugs that treat everything from your standard, really annoying urinary tract infection all the way up to walking pneumonia, MRSA, and even exposure to anthrax.

Okay, so the stakes are definitely high.

The stakes are incredibly high.

Yeah.

And the margin for error with these is, well, it's razor thin.

What we're going to see today is that these drugs are really powerful weapons, but they all have these intricate safety catches.

And if you don't understand the mechanism, the how and the why, you can cause serious, sometimes permanent damage to a patient.

What kind of damage are we talking about?

You could literally snap a tendon.

You could cause a seizure.

You can destroy a patient's kidneys.

It's serious stuff.

So our mission today, then, is to deconstruct this arsenal.

We're going to take these weapons apart, look at the firing mechanisms, and really understand how to use them without, you know, blowing ourselves up.

That's the plan.

And we've got three main categories to get through today.

First, we have the antifleets.

I call that the starvation strategy.

Okay.

Then we'll get into the floriculones.

The DNA snappers.

The DNA snappers.

And finally, that group of unique specialist drugs like nitroferrantone and daptomycin that I call the special forces.

All right.

Let's start with the starvation strategy.

The antifleets.

This whole section seems to revolve around one single molecule, folate or folic acid.

Now I see folate on my cereal box.

It's vitamin B9.

I know I need it.

Why are we weaponizing it against bacteria?

Well, to understand the weapon, you really have to understand the supply chain.

Both humans and bacteria absolutely need folate.

It is completely non -negotiable for life.

What do we actually use it for?

What's its job?

Its main job is to help make DNA.

Specifically, folate derivatives are responsible for donating these single carbon atoms to synthesize purines and thymidine.

The building blocks of DNA.

A literal building block.

So if you don't have folate, you cannot make DNA.

If you can't make DNA, you can't replicate.

You can't divide.

The cell dies.

It's that simple.

Okay.

So it's essential for life for both of us.

But if we both need it, how do we target the bacteria without also starving ourselves?

And this is the beautiful elegance of evolutionary divergence.

Humans and all mammals, for that matter, are biologically lazy when it comes to folate.

Lazy.

We don't build it.

We just eat it.

We get it from our diet, from spinach, from fortified cereal, from supplements.

We have a specific transport system that just pulls folate out of our gut and delivers it to ourselves.

So we're consumers.

We are consumers, exactly.

Bacteria, on the other hand, are producers.

Most bacteria lack that transport system.

They can't just absorb folate from the environment around them.

Their cell walls are actually impermeable to it.

So they are forced to build it from scratch inside their own cytoplasm.

Have a little internal factory.

Precisely.

And that factory is our target.

If we can shut down their factory, the bacteria starve to death because they can't import the finished product.

Meanwhile, our human cells are completely unaffected because we don't have a factory to begin with.

We just, you know, keep eating our salad.

That is the aha moment.

It's all about synthesis versus consumption.

So let's walk onto that factory floor.

The text references figure 40 .1, which lays out this whole assembly line.

What are the raw materials?

So the bacteria starts with two main components.

One is a molecule called pteridine.

The other is a substance called paeba.

Paeba.

Paramino benzoic acid.

Paeba.

I feel like I've seen that on old sunscreen bottles from like the 90s.

You probably have.

It's a common chemical building block.

So the bacteria takes pteridine and paba, and it uses an enzyme.

This is the first worker on the line called dihydrocuret synthase.

And this enzyme just stitches them together to make a new molecule, dihydroptorate.

Okay.

So that's step one.

Pteridine plus paba equals dihydroptorate.

Right.

Then the assembly line continues.

They add another piece, glutamate, to that molecule to make dihydrofolate.

And then comes the second critical worker, another enzyme called dihydrofolate reductase.

This enzyme takes that dihydrofolate and, well, it reduces it to tetrahydrofolate.

Tetrahydrofolate.

And that's the final product.

That's what they need.

That is the active gold.

That is the cofactor that actually goes off to help build the DNA.

So it's a two -stage process with two key enzymes.

We've got dihydroptorate synthase at the start and dihydrofolate reductase near the end.

I'm going to guess our drugs are going to sabotage these specific workers.

You are exactly right.

And this brings us to the first class of drugs, the sulfonamides.

These are the sulfa drugs.

And historically, I mean, these are ancient.

How ancient are we talking?

We are talking 1930s.

This is actually before penicillin was widely available.

There was this red dye called Prontosil.

And scientists found that it could cure bacterial infections in mice.

But, and this was the weird part, it didn't work in a test tube.

Wait, it worked in the living animal, but not in the Petri dish.

Why would that be?

Because Prontosil was what we call a pro drug.

It wasn't active on its own.

It had to be metabolized by the mouse's liver, which broke it down into the actual active ingredient,

a molecule called sulfanilamide.

That discovery just changed medicine overnight.

Wow.

So how does this sulfanilamide actually break the factory?

What does it do?

It's a brilliant case of mistaken identity.

If you look at the molecular structure of a sulfonamide, it looks almost identical to PAYBA.

It's what we call a structural analog.

PAYBA, the raw material we've just mentioned.

Exactly.

So that first enzyme, dihydroptorate synthase, is floating around looking for PAYBA to start building folate.

Suddenly, it sees a sulfonamide molecule float by and thinks, aha, here is my PAYBA, and it grabs it.

It grabs the decoy.

It grabs the decoy.

But the sulfonamide doesn't fit quite right into the reaction site.

It essentially jams the active site of the enzyme.

It's a competitive inhibitor.

So the enzyme is now occupied with this fake ingredient, and it can't process the real PAYBA.

The whole assembly line grinds to a halt at step one.

So no dihydroptorate gets made, which means no folate, which means no DNA.

Correct.

But there is a vulnerability here.

You use the keyword competitive inhibition.

That implies there's a contest going on.

A contest between the drug and the real PAYBA.

Yes.

It's a numbers game.

If the bacteria can somehow flood the system with a massive amount of real PAYBA, they can eventually outcompete the drug.

The enzyme will eventually bump into the real stuff just by sheer probability.

And this is why sulfonamides don't work well in the presence of pus or tissue breakdown products.

So that pus is full of PUP.

Exactly.

Pus and necrotic tissue are full of cellular debris, and when cells break down, they release huge amounts of PAYBA and even thymidine.

It basically gives the bacteria free lunch, letting them bypass our blockade entirely.

That is a fascinating clinical pearl.

So don't use sulfa drugs on a big pus -filled abscess because the pus itself is basically the antidote to the drug.

You've got it.

Now let's look at the second drug that often pairs with this.

Trimethoprim.

Okay.

So where does trimethoprim strike on the assembly line?

Trimethoprim is, well, it's a bit smarter.

It waits for step three.

Remember that second key enzyme, dihydrofolate reductase, the one that makes the final active tetrahydrofolate?

The finisher.

Trimethoprim attacks the finisher.

It inhibits dihydrofolate reductase.

Now, wait a minute.

You said earlier that humans don't have the first enzyme.

So sulfur drugs are safe for us, but do we have the reductase?

We must, right.

We have to be able to process the folate that we eat.

We do.

We absolutely have dihydrofolate reductase in ourselves.

So if trimethoprim blocks that enzyme, aren't we blocking our own DNA synthesis?

That sounds less like an antibiotic and more like, I don't know, chemotherapy.

And you are spotting the exact danger.

If trimethoprim worked equally on bacteria in humans, it would be a poison.

But the safety lies in its affinity.

This is pure chemistry magic.

Trimethoprim binds to the bacterial version of the enzyme about a hundred thousand times more strongly than it binds to the human version.

A hundred thousand times.

That's the ratio.

It's an incredible difference.

So at the doses we give to a patient, the drug practically ignores the human enzyme.

It just bounces off.

But it latches onto the bacterial enzyme like a vice.

That selectivity is the only reason this drug is usable in humans.

So we have this two -pronged attack.

Sulfonamides hit the start of the line.

Trimetham hits the end.

Before we talk about combining them, let's talk about how the body handles these drugs, the pharmacokinetics.

Let's focus on the sulfonamides first.

They're generally well absorbed when you take them orally.

They distribute pretty much everywhere.

They get into tissues, fluids.

They even cross the placenta to the fetus.

And they get into the cerebrospinal fluid, the CSF.

Which would be good for treating something like meningitis, at least in theory.

In theory, yes.

But the real story with sulfonamides is in the liver.

The liver tries to metabolize these drugs to get rid of them.

And it uses a process called anacetylation.

Anacetylation.

What does that actually do to the molecule?

It just tacks an acetylgroom onto it.

Usually the liver does this to make things more water soluble, easier to excrete in the urine.

But with sulfonamides, there's a glitch in the system.

The acetylated metabolites, the waste products, are actually less soluble in water than the original drug was.

This seems like a pretty significant design flaw in our biology.

It's very problematic.

So these less soluble metabolites travel to the kidneys to be filtered out into the urine.

But as the urine gets concentrated in the tubules, the water is reabsorbed.

If the concentration of the drug gets too high and the solubility is low.

It turns back into a solid.

It precipitates.

It forms crystals.

And we call this crystaluria.

So you are essentially forming jagged little crystals inside the delicate tubes of the kidney.

That sounds awful.

It is.

It can cause bleeding, obstruction, and even acute kidney injury.

It's like pouring sand in the gears of your engine.

How do we prevent that from happening?

Dilution.

The solution to pollution is dilution.

Patients on sulfonamides must be told to drink copious amounts of water.

You have to keep the urine flow high to just flush those metabolites out before they have a chance to settle and crystallize.

So drink plenty of fluids isn't just generic advice here.

It's a direct prescription to save your kidneys.

It is absolutely mandatory.

Now, what about trimethoprim's pharmacokinetics?

There's this interesting concept mentioned in the text called ion trapping.

This sounds like something out of Ghostbusters.

It's a very cool physical property.

The trimethoprim is a weak base.

Now, if you think back to general chemistry, a weak base becomes more ionized.

It picks up a charge in an acidic environment.

Okay.

And when a drug becomes ionized?

It becomes charged.

And charged molecules have a very, very hard time crossing cell membranes.

They get stuck.

They get trapped.

So if trimethoprim flows into a compartment of the body that happens to be acidic, it gets ionized and then it can't leave.

Exactly.

It accumulates there.

The concentration can build up to be much higher in that compartment than it is in the blood.

So where in the body are we acidic?

The prostate fluids and the vaginal fluids are both more acidic than blood plasma.

Which is incredibly convenient if you're trying to treat, say, bacterial prostatitis or vaginitis.

It's a perfect example of pharmacokinetic serenity.

The drug naturally concentrates itself exactly where the infection is likely to be.

Okay.

So we have the chemistry down.

Now let's talk about putting them together, the power couple.

In clinical practice, I almost never see sulfamethoxazole or trimethoprim prescribed alone.

It's always the combination TMP, SMX, you know, Bactrim or Ceptra.

Why is that?

It's all about synergy.

This is the classic textbook example of one plus one equals three.

Explain the math for us.

Well, if you use a sulfonamide alone, you block step one of the factory.

But maybe the blockade is only, say, 90 % effective.

Some bacteria might survive.

They just grow slower.

We call that bacteriostatic.

If you use trimethoprim alone, you block step three.

Again, maybe some slip through.

Also bacteriostatic.

But if you use both at the same time.

If you block the front door and the back door of the factory simultaneously, nothing gets made.

The bacteria completely run out of DNA components and they die.

The combination becomes bactericidal.

It actively kills them.

So why is sulfamethoxazole specifically?

I mean, there are other sulfa drugs.

Why is this the one that's always partnered with trimethoprim?

It comes down to the stopwatch.

The pharmacokinetics.

You want two drugs that stay in the body for about the same amount of time.

If you took a combination where one drug wore off in two hours and the other lasted 12 hours, you'd spend 10 of those hours with only one drug working.

You'd lose the synergy.

And you'd probably start breeding resistance during that time.

Exactly.

Both trimethoprim and sulfamethoxazole have a half -life of roughly 10 hours.

They are perfectly matched partners.

They enter the system together, they work together, and they leave together.

It's a pharmacokinetic match made in heaven.

There is a little bit of confusing math in the text about the dosing ratio, though.

It says the optimal ratio in the blood to kill bacteria is 20 parts sulfamethoxazole to one part trimethoprim.

So a 20 to 1 ratio.

Right.

But the pill itself is formulated as a 5 to 1 ratio.

Why don't we just put a 20 to 1 ratio in the pill if that's what we want in the blood?

This is a great question.

And it comes down to a concept called volume of distribution.

Trimethoprim is a very lipophilic drug.

It loves fat.

It loves tissues.

So when you swallow it, it rushes out of the bloodstream and soaks into the organs and fatty tissues.

So it leaves the blood very quickly.

It leaves the plasma, yes.

Sulfamethoxazole, on the other hand, tends to stay in the plasma more.

So to get that one part of trimethoprim to stay in the blood, you essentially have to overdose it relative to the plasma target, knowing that most of it is going to run off and distribute into the tissues.

Ah, I see.

So we give a 1 to 5 ratio in the mouth, and after the trimethoprim scatters into the tissues, what's left behind in the blood settles out to that perfect 1 to 20 ratio.

Precisely calculated pharmacokinetics.

It's pretty clever.

So what are we treating with this power couple?

What's its main clinical spectrum?

It's the workhorse for the Enterobacteriaceae family.

So that means your E.

coli, your Klebsiella, your Proteus, basically the usual suspects for uncomplicated urinary tract infections.

But there is a big caveat on resistance.

A huge one.

Because we've used this drug so much for so long, bacteria have learned to fight back.

The text makes a really important point that for empiric treatment of a UTI, that means treating it before you get the lab results back, you should only use TMP -SMX if the local resistance rate in your community is known to be less than 20%.

So if more than 1 in 5 people in your town have resistant E.

coli, you probably shouldn't use this drug blindly.

Correct.

You're essentially flipping a coin with the patient's health at that point.

There is another very specific and very important use for this drug outside of UTIs.

It seems to be a lifesaver for immunocompromised patients.

Yes.

This is the drug of choice for Pneumocystis Geriveci Pneumonia, or PCP.

This is a fungal -like organism that causes absolutely devastating pneumonia in people with advanced HIV AIDS, or those on heavy chemotherapy or transplant medications.

And also an organism called Nocardia.

Yes, Nocardia is a bacteria found in soil that can cause really nasty brain abscesses and lung infections, again, in people with weakened immune systems.

TMP -SMX is the silver bullet for both of those.

Before we leave the antiphilates, we have to look at the warning label.

We've already mentioned the kidney stones from the sulfur component.

What else can go wrong?

Well, remember how we said trimethopren is 100 ,000 times more selective for the bacterial enzyme?

That's great, but it's not infinite.

If you treat for a long time, or at very high doses, or the patient is already borderline deficient in folate to begin with, like an alcoholic or a pregnant woman, you can start to see some effects on human DNA synthesis.

And where would that show up first?

In the cells that are dividing the fastest?

Exactly.

The bone marrow.

You can get bone marrow suppression.

So things like anemia.

Megaloblastic anemia.

Specifically, you get these big, clumsy red blood cells that don't work right.

You can also get leukopenia -low white blood cells and thrombocytopenia -low platelets.

You really have to watch the blood counts on long -term therapy.

And what about the skin?

Sulfa allergies are famous.

They are.

It can be just a mild rash, but the thing we always fear is Stevens -Johnson syndrome, or SJS.

Can you describe that for us?

What is SJS?

It is a horrific, life -threatening hypersensitivity reaction.

The immune system basically attacks the skin and the mucous membranes.

The skin blisters and then peels off in sheets.

It looks like the patient has a massive thernal burn and it's a true medical emergency.

So if a patient on a sulfa drug calls and says, I think I have a rash, you don't just tell them to put some lotion on it.

No.

You stop the drug immediately.

You do not gamble with SJS.

And there's one final genetic trap mentioned.

G6PD deficiency.

Right.

Glucose 6 -phosphate dehydrogenase deficiency.

It's a genetic enzyme defect and is particularly common in people of Mediterranean or African descent.

This enzyme's job is to protect red blood cells from oxidative stress.

And sulfonamides are drugs that cause oxidative stress.

So if you give a sulfur drug to a G6PD deficient patient, what happens?

The red blood cells can't handle the stress they burst.

It's called hemolytic anemia.

The patient turns yellow from jaundice and their blood count just crashes.

It's a classic board exam scenario, but it's also a real clinical disaster if you miss it.

Okay.

That is a very complete story on the antifoulet.

From the factory floor all the way to the kidney crystals.

Let's shift gears and move to part two.

The DNA snappers.

The fluoroquinolones.

The floxacins.

Ciprofloxacin, levofloxacin.

Moxifloxacin.

Ciprolivquin, avlox.

You gave this class a very visceral nickname, the twist and snap.

I did because that is literally what happens at the molecular level.

To really get these drugs, you have to visualize the physical problem of DNA storage inside a bacterium.

Okay, paint the picture for us.

So bacterial DNA is this huge molecule.

It's a closed circle and it is crammed into a tiny little cell.

To make it fit is coiled up incredibly tightly like a spring that's under a ton of pressure.

Like one of those snakes in a can jokes.

Exactly like a snake in a can.

Now when the bacteria wants to replicate its DNA, it has to unzip that double helix to read the code.

Imagine unzipping an old twisted coiled phone cord.

Oh, I remember those.

If you pull the middle apart, the coils ahead of where you're pulling get tighter and tighter and all knotted up.

Precisely.

That tightening is called positive supercoiling.

As the DNA replication machinery pushes forward, the tension ahead of it becomes unbearable.

If that tension isn't relieved, the DNA will just knot up and the replication machinery will stall.

The whole process just dies.

So the bacteria needs some kind of pressure relief valve.

It has one.

It's a remarkable enzyme called DNA gyrase, which is also known as depoisomerase too.

And what does gyrase do?

It's incredible to watch.

Molecularly.

It grabs the DNA ahead of the tension.

It physically cuts both strands.

It just snaps them open.

Then it passes another segment of DNA through that gap, which effectively unwinds the knot.

And then, and this is the crucial part, it glues the cut strands back together perfectly.

So it cuts, it untangles, and that reseals.

It's a controlled demolition and reconstruction happening thousands of times every minute.

So where do the fluoroquinolines interfere in that process?

They are saboteurs.

They bind to the DNA gyrase enzyme while it is holding the cut DNA.

They essentially freeze the enzyme in that state.

Wait, so the enzyme makes the cut in the DNA and then the drug freezes it there?

Yes.

It prevents the resealing step.

It locks the molecular scissors in the open position with the DNA still cut in half.

So you're just left with a bunch of fragmented DNA?

You're left with double strand breaks all over the chromosome.

And when the replication fork, the DNA copier, comes rushing down the track and hits one of those breaks, the whole chromosome just falls apart.

It is irreversible and it is fatal to the cell.

That is violent.

It's not just starving them.

This is actively shredding their blueprint.

It is bactericidal in the truest sense of the word.

The text makes a distinction between Gram -negative and Gram -positive targets here.

Is it the same mechanism for both types of bacteria?

It's similar, but the primary targets are slightly different.

In Gram -negative bugs like E.

coli, the main target is DNA gyrase, which manages that supercoiling like we just described.

In Gram -positive bugs like Staph aureus, the main target is a cousin enzyme called depoizomerase pete.

And what does depoizomerase pete do?

It handles the very end of the replication process.

When a bacteria divides, you end up with two interlinked circles of DNA like two rings in a magic trick.

They're called catnans.

Topo IV's job is to cut one ring to let the other pass through so the two daughter cells can actually separate.

It's a process called decatination.

So the fluoroquinolones stop the daughter cells from separating?

Yes.

They freeze topo IV, leaving the two daughter chromosomes locked together.

The cells can't fully separate.

The DNA breaks and they die.

Brutal either way.

Now let me talk about the drugs themselves.

How do we get them into the patient?

What's the administration like?

One of the huge advantages of the fluoroquinolones is their bioavailability.

Most of them are excellent when taken orally.

I think levofloxacin is something like 99 % bioavailable.

Which means taking the pill is just as strong as getting the IV.

Exactly.

And this is a huge deal.

It allows us to treat very serious infections at home.

You can send a patient out of the hospital with pills instead of keeping them there for days just for an IV drip.

There is a massive but here regarding absorption, the chelation problem.

This is the number one counseling point for any pharmacist dispensing these drugs.

Fluoroquinolones are chemical magnets for what we call divalent and trivalent occasions.

Can you translate that for us?

They bind aggressively to positively charged metals.

So calcium, magnesium, iron, zinc, aluminum.

So milk, dairy products.

Milk, yogurt, calcium supplements, multivitamins that have iron or zinc, and antacids like malox or Tums which are full of magnesium and aluminum.

So what happens if I take my Cipro with a big glass of milk?

The calcium in the milk binds to the Ciprofloxacin molecule right there in your stomach.

They form this giant insoluble clot.

It's called a chelate.

Your body cannot absorb this clot.

It just passes right through your GI tract and out into the toilet.

So the drug never even reaches your bloodstream.

Correct.

You have essentially taken a very expensive placebo.

Right.

And your infection goes completely untreated.

That is a critical, critical failure.

It is.

You have to separate the doses.

The rule of thumb is to take the drug two hours before, or at least four hours after, any dairy, vitamins, or antacids.

Got it.

Now let's classify these drugs.

They seem to come in generations.

Let's start with the old heavyweight, Ciprofloxacin.

Cipro, yes.

This is the quintessential gram -negative sniper.

It is incredibly potent against enteric bacteria, the stuff that lives in your gut.

So E.

coli, salmonella, shigella.

The bugs that cause traveler's diarrhea.

Yes.

And it is also a powerhouse against Pseudomonas aeruginosa, which is a really difficult to kill bug you often see in hospitals.

And as we noted in the intro, it is the first -line drug for exposure to anthrax.

If Cipro is so good against all those serious bugs, why don't we just use it for everything?

Why not for, say, pneumonia?

Because Cipro has an Achilles heel, so to speak.

It is very, very weak against streptococcus pneumonia, which is the number one bacterial cause of community -acquired pneumonia.

So using Cipro for pneumonia is a definite no -go.

It's a dangerous mistake.

You might cheer a UTI they happen to have, but you'd be letting their pneumonia kill them.

So we invented newer ones to fix that problem, the respiratory fluoroquinolones.

Right.

Levofloxacin and moxafloxacin.

Scientists tweaked the molecule.

They kept all that great gram -negative killing power, but they extended the spectrum to reliably cover gram -positives, specifically strep pneumo.

So these are the broad spectrum versions of the class.

Yes, they are excellent choices for community -acquired pneumonia or CAP.

They kill the pneumococcus, but they also kill the atypicals.

The atypicals.

Who are they?

These are bacteria that either don't have a normal cell wall or that live inside our cells.

Things like mycoplasma, which causes walking pneumonia, chlamydia pneumonia, and legionella.

Legionella, as in legionnaire's disease.

That's the one.

Fluoroquinolones have excellent activity against it.

There is a newer drug mentioned in the chapter, delafloxacin.

What's special about that one?

Delafloxacin is unique because it works really well in acidic environments.

And why does that matter clinically?

Well, an abscess is acidic.

A pocket of pus is acidic.

A lot of antibiotics actually lose their charge and their potency in an acidic pH.

Delafloxacin stays active.

It's also got reliable activity against MRSA, which most of the other quinolones do not.

So we have these incredibly powerful weapons.

They snap DNA.

They act like snipers.

But this chapter is really heavy on the warning labels.

The toxicity section for fluoroquinolones is frighteningly long.

It is a plethora of problems.

And this has genuinely changed how we practice medicine.

I mean, 10, 15 years ago, we handed out Cypro like it was candy.

Now we are very, very hesitant.

Let's break down the potential damage.

Start with the connective tissue.

Musculoskeletal toxicity.

For whatever reason, these drugs have a high affinity for cartilage and tendons.

You seem to disrupt the cartilage matrix.

And what's the clinical result of that?

Tendonitis.

Pain and inflammation of the tendon.

And even worse, actual tendon rupture.

You mean the tendon just snaps in half.

Yes.

Specifically, the Achilles tendon is the most common one.

Imagine you're taking an antibiotic for a simple sinus infection.

You go for a light jog and pop your Achilles tendon just snaps.

That is absolutely devastating.

It is.

The FDA has put a black box warning on the entire class for this.

The risk is much higher in patients over 60.

Anyone taking corticosteroids and solid organ transplant patients.

Is this why we don't give Cypro to children?

I've always heard that.

That is exactly why we are terrified of damaging the drawing cartilage in children's joints, what's called the epiphyseal plates.

So it is generally contraindicated in anyone under 18 and also in pregnant women.

Okay.

What about the nervous system?

Peripheral neuropathy.

This can start out subtly.

Some tingling, some numbness in the fingers or toes.

But it can progress to shooting pains and permanent nerve damage.

And the scary part is it can happen after just a few doses.

Permanent.

Potentially permanent.

Yes.

And then you have the central nervous system effects.

Confusion, hallucinations, and even seizures.

Speaking of getting the jitters, there is a very specific interaction with coffee here that the text points out.

Ah, yes.

The caffeine connection.

Cyprofloxacin specifically inhibits a liver enzyme called CYP1A2.

And what does CYP1A2 normally do?

Its main job in the body is to metabolize caffeine and a related drug called theophiline.

So if I take CYPRO, I turn off the enzyme that breaks down my morning coffee.

Exactly.

So you drink your one usual cup of coffee, but your body can't get rid of the caffeine.

The caffeine levels just rise and rise and rise.

It's like you drank 10 espressos, you get intensely anxious, your heart races, you can't sleep.

It can be really unpleasant.

So CYPRO plus Starbucks is basically a recipe for a panic attack.

It absolutely is.

What about the heart rhythm?

There's a warning about that too.

QT prolongation.

This refers to the electrical recharging time of the heart muscle between beats.

If you prolong that interval, you create a dangerous window where the heart can slip into a chaotic, fatal rhythm called torsades de pointe.

Which can lead to cardiac arrest?

It can.

So you have to be very careful giving these drugs to patients who are already on other heart medications that also affect the QT interval.

And finally, blood sugar.

Dysglycemia.

For reasons we don't fully understand, these drugs can cause dangerous drops in blood sugar hypoglycemia or sudden spikes hyperglycemia.

For a patient with diabetes on insulin, taking CYPRO can make their blood sugar management completely chaotic and unpredictable.

So listing all of that out, tendons, nerves, seizures, anxiety, heart arrhythmias, blood sugar swings, it really changes the risk -benefit calculation.

It does.

And that brings us perfectly to the clinical case study in box 40 .1.

Right.

Let's look at this.

We have a 27 -year -old woman who comes in.

She's had two days of urinary urgency and burning.

No fever, no back pain.

This is a textbook uncomplicated cystitis.

The infection is just in the bladder.

It hasn't moved up to the kidneys.

She had one of these infections two years ago.

The doctor prescribes TMP SMX, our friend trimethoprim sulfamethoxazole.

A solid, appropriate choice.

My question is,

why not CYPRO?

We just said CYPRO is the gram -negative sniper.

We know it concentrates on the urine.

It kills E.

coli.

Why not use the bigger gun to get rid of it faster?

For two really important reasons.

First is antibiotic stewardship.

We want to save the big guns for when we really need them, for more serious infections.

But second, and more importantly, is safety.

The Infectious Diseases Society of America, the IDSA,

actually changed their guidelines on this.

They explicitly stated that for uncomplicated cystitis, the risk of serious side effects from fluoroquinolones like tendon rupture and nerve damage outweighs the benefits.

Meaning you should not risk snapping a 27 -year -old woman's Achilles tendon just to treat a simple bladder infection that something like TMP SMX can handle safely.

Exactly.

You don't use a bazooka to kill a housefly, especially if the bazooka might blow your own foot off in the process.

That really puts it in perspective.

Okay, we have covered the factory saboteurs and the DNA snappers.

Now let's open up that special forces drawer.

These are the drugs that don't really fit into a big family.

They're lone wolves.

All right, let's go rapid fire.

First up, nitroferantoin.

This is another UTI drug, right?

Macrobid.

Exclusively a UTI drug.

The text calls it a urinary tract antiseptic.

Why antiseptic?

That sounds like Listerine for your bladder.

That's actually a pretty good analogy.

It's because it only works in the urine.

When you swallow the pill, it gets absorbed.

But the body excretes it into the urine so rapidly that it never builds up to therapeutic levels in the blood or tissues.

So you can't use it for a blood infection.

You can't use it for a kidney infection.

Because the kidney tissue itself relies on blood levels for treatment.

Exactly.

But down in the bladder, floating in the urine, the concentration is massive.

It's great against E.

coli, enterococcus, and another common UTI bug called staph saprophyticus.

What about the name macrodanton?

The text mentions the macrocrystalline form.

That's a formulation trick to make it more tolerable.

The old original version had very small crystals that dissolved too fast in the stomach and made people really nauseous.

The macrocrystals are bigger.

They dissolve slower, so it's much easier on the stomach.

Is there a scary side effect we need to know about?

There is.

Pulmonary fibrosis.

It's rare.

But if an elderly patient is on this drug for months and months for UTI suppression,

their lungs can develop scar tissue.

You have to watch for a new persistent cough.

OK.

Next lone wolf.

Daptomycin.

This one sounds pretty sci -fi.

It is.

The mechanism is futuristic.

Daptomycin is a cyclic lipopeptide.

The best way to think of it is as a dagger with a fatty or lipid handle.

A lipophilic tail.

Exactly.

It takes that lipid tail and it inserts it into the bacterial cell membrane.

It literally punctures the membrane.

Like popping a balloon.

It's very much like that.

It causes rapid depolarization of the membrane potential.

The cell loses its electrical charge.

Potassium ions just leak out.

The bacteria can no longer synthesize DNA or protein.

It dies very quickly.

What does it kill?

What's its spectrum?

Gram -positives.

But specifically, the really bad gram -positives.

It's a go -to for MRSA methicillin -resistant staph aureus and VRE vancomycin -resistant enterococcus.

So this is a big gun we use for serious skin infections and blood infections caused by superbugs.

Correct.

But here is the massive high -yield must -know warning.

Do not use daptomycin for pneumonia.

Why not?

If it kills MRSA and my patient has MRSA pneumonia, why won't it work?

It seems logical.

This is the surfactant trap.

Our lungs, specifically the alveoli, are lined with a substance called surfactant.

It's a phospholipid -rich substance that keeps our air sacs from collapsing.

And daptomycin has that lipid tail.

It loves lipids.

It loves lipids too much.

If you put daptomycin in the lung, it completely ignores the bacteria and just binds irreversibly to the surfactant.

The lung tissue essentially soaks up and neutralizes the drug.

So the drug gets sequestered by the lung fluid itself and never even touches the bacteria it's supposed to kill.

That is exactly what happens.

You can have a patient with perfectly susceptible bacteria in their lungs, but if you use daptomycin to treat their pneumonia, they will die because the drug physically cannot reach its target.

That is a critical mechanism to practice connection right there.

What about toxicity?

Muscles.

It causes myopathy and in severe cases, rhabdomyolysis muscle breakdown.

You have to monitor a blood test called CPK weekly to make sure the muscles aren't being damaged.

Okay, next up on the list, polymixin B.

This is a really old drug that we basically brought back from the dead out of desperation.

It acts like a caseinic detergent.

Detergent like dish soap.

Chemically, the mechanism is very similar.

It's positively charged and it's attracted to the negatively charged phospholipids in the bacterial membrane.

It just wedges in there and dissolves it.

It literally tears the cell wall apart.

That sounds incredibly effective, but also incredibly dangerous to our own cells.

It is.

Cell membranes are cell membranes.

It is very toxic to humans if it's given systemically.

It is famous for destroying kidneys.

It's nephrotoxic and damaging nerves.

It's neurotoxic.

So why on earth do we still use it?

Well, we mostly use it topically.

It's actually one of the ingredients in neosporin ointment.

But in the hospital, we are forced to use it IV as a last resort agent for multi -drug resistant gram -negative superbugs that are resistant to everything else we have.

It's the nuclear option.

Two more to go.

Rifaximin.

This is a weird one.

It's a derivative of a tuberculosis drug, rifampin.

But it is specifically designed to be not absorbed.

Meaning it just stays in the gut.

Something like 99 .6 % of the dose stays in the GI tract.

It travels down, kills bacteria along the way, and then just leaves the body in the stool.

What is that useful for?

A few things.

Traveler's diarrhea.

It's great for cleaning out the pathogenic E.

coli.

It's used for some types of IBS to alter the gut flora and reduce bloating.

And most interestingly, for hepatic encephalopathy.

That's the confusion that happens in severe liver failure, right?

Patients with liver failure can't process ammonia.

A lot of that ammonia is produced by bacteria in the gut.

Rifaximin kills off those ammonia -producing bacteria, which lowers the ammonia levels in the blood and can literally wake a patient up from a coma.

So it treats the brain by cleaning up the gut.

That's very cool.

And the last one.

Fadaxamisin.

This is the C.

diff sniper.

Clostridioids difficile, or C.

diff, is that nasty diarrheal infection that can happen when broad -spectrum antibiotics wipe out all your good gut bacteria.

So usually antibiotics are the cause of C.

diff.

How do we use another antibiotic to treat it?

Well, traditionally we've used drugs like vancomycin, but fadaxamisin is special.

It inhibits an enzyme called RNA polymerase.

But the key is that it has a very, very narrow spectrum of activity.

It is fantastic at killing C.

diff, but it barely touches the other good bacteria, the normal flora, in your colon.

So it takes out the one bad guy, but it leaves the police force, the normal gut microbiome intact, to keep the peace.

That's the perfect analogy.

And because it does that, it leads to much lower recurrence rates.

The infection is far less likely to come back because the underlying ecosystem hasn't been completely destroyed.

Wow.

We have covered a massive amount of ground.

From the factory sabotage of the antiphilates to the DNA snapping of the quinolones, and now to the membrane popping of daptymycin and the others.

It's a very diverse arsenal.

And I hope the one thing you, the listener takeaway, is that the mechanism of action isn't just trivia for an exam.

Right.

Knowing that daptymycin binds to lungs surfactant isn't just a fun fact.

It's a piece of knowledge that saves a life.

Knowing Cipro interacts with your coffee prevents a panic attack.

Knowing TMP SMX needs water prevents kidney stones.

Mechanism informs practice.

There's the golden rule of pharmacology.

Before we sign off, leave us with one final thought.

What's the big picture takeaway from this whole chapter?

I want you to think about the arms race,

the constant evolution.

We saw how sulfonamides were miracle drugs in the 1930s.

Then bacteria learned to overproduce PBAY to compete with them.

We saw how quinolones were miracle drugs in the 90s.

Now bacteria are mutating their gyrase and building efflux pumps to literally spit the drug back out of the cell.

It's a constant escalation.

It is.

We are now relying on these last resort drugs like polymixin and daptymycin, drugs that attack the fundamental structure of the cell membrane.

But evolution doesn't stop.

Bacteria are already figuring out how to alter their membrane charge to resist these drugs.

Our stewardship, using the right drug for the right bug at the right time and avoiding them when they're not needed is the only thing that buys us more time in this race.

A very sobering reminder of why we need to respect these powerful agents, not just prescribe them.

Thank you so much for breaking all of this down for us.

It was my pleasure.

And thank you, the learner, for joining us on this deep dive into Chapter 40.

Thanks for listening from the Last Minute Lecture Team.

Thanks for listening from the Last Minute Lecture Team.